martes, 21 de mayo de 2024

UK's asylum process takes a toll on the health and wellbeing of people seeking sanctuary

https://www.news-medical.net/news/20240521/UKs-asylum-process-takes-a-toll-on-the-health-and-wellbeing-ofe280afpeople-seeking-sanctuary.aspx

Fake news unmasked: Emotional features boost fake news detection accuracy on social media

https://www.news-medical.net/news/20240520/Fake-news-unmasked-Emotional-features-boost-fake-news-detection-accuracy-on-social-media.aspx

NIAID Research Team Develops 2nd Model of Crimean-Congo Fever

https://www.niaid.nih.gov/news-events/cchf-model?utm_campaign=+60675239&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term= A NIAID research team has developed an additional nonhuman primate study model for Crimean-Congo hemorrhagic fever (CCHF), providing an alternative for development of vaccines and therapeutics. They hope the work, published in npj Vaccines, will lead to a widely available replicating RNA-based vaccine that they are testing against CCHF. The WHO lists CCHF virus as a priority pathogen for development of vaccines. In some outbreaks CCHF has had a case fatality rate up to 40%. Cynomolgus macaques (CM) are the preferred model available to study how the virus causes infection and disease in people. But during the COVID-19 pandemic, CMs were prioritized for other research, and NIAID scientists sought to develop an alternative model using rhesus macaques (RM) to continue vaccine work. RMs infected with CCHFV developed mild-to-moderate disease, similar to the CM model and consistent with disease in humans. The scientists then showed that the experimental vaccine provided six infected RMs with a protective immune response that controlled CCHF virus. The results are consistent with their findings using CMs and support continued advancement of the vaccine into human trials.

Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer

https://www.cancer.gov/news-events/cancer-currents-blog/2024/kidney-cancer-pembrolizumab-increases-survival?cid=eb_govdel The immunotherapy drug pembrolizumab (Keytruda) has rapidly become one of the most widely used cancer treatments. Based on updated results from a large clinical trial, the drug is now part of an important milestone in the treatment of kidney cancer—specifically, clear-cell renal cell carcinoma, the most common form of the disease.

Clinical Center News

https://www.cc.nih.gov/about/news/newsletter/index.html

Unseen details of human brain structure revealed

https://www.nih.gov/news-events/nih-research-matters/study-reveals-unseen-details-human-brain-structure Fully understanding how the human brain works requires knowing the relationships between the various cells that make up the brain. This entails visualizing the brain’s structure on the scale of nanometers in order to see the connections between neurons.

Study suggests approach for treating rare disorder

https://www.nih.gov/news-events/nih-research-matters/study-suggests-approach-treating-rare-development-disorder Research into rare diseases and disorders is hampered by the limited number of people available to participate in studies. Many rare diseases and disorders also lack animal models that can help scientists perform early testing of new treatments.